Australian patterns of prostate cancer care: Are they evolving?

详细信息    查看全文

• 作者：Jonathon Lo¹ ; Nathan Papa¹ ; Damien M. Bolton¹ ; Declan Murphy² ; Nathan Lawrentschuk¹ ; ² ; ³ ; ^{lawrentschuk@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Brachytherapy ; Lymph node excision ; Mass screening ; Prostatectomy ; Prostatic neoplasms
• 刊名：Prostate International
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：4
• 期：1
• 页码：20-24
• 全文大小：658 K

文摘

Approaches to prostate cancer (PCa) care have changed in recent years out of concern for overdiagnosis and overtreatment. Despite these changes, many patients continue to undergo some form of curative treatment and with a growing perception among multidisciplinary clinicians that more aggressive treatments are being favored. This study examines patterns of PCa care in Australia, focusing on current rates of screening and aggressive interventions that consist of high-dose-rate (HDR) brachytherapy and pelvic lymph node dissection (PLND).

Methods

Health services data were used to assess Australian men undergoing PCa screening and treatment from 2001 to 2014. Age-specific rates of prostate-specific antigen (PSA) screening were calculated. Ratios of radical prostatectomy (RP) with PLND to RP without PLND, and HDR brachytherapy to low-dose-rate (LDR) brachytherapy were determined by state jurisdictions.

Results

From 2008, the rate of PSA screening trended downward significantly with year for all age ranges (P < 0.02) except men aged ≥ 85 (P = 0.56). PLND rates for 2008–2014 were lower than rates for 2001–2007 across all states and territories. From 2008 to 2014, PLND was performed ≥ 2.7 times more frequently in New South Wales and the Australian Capital Territory than in other jurisdictions. Since 2007, brachytherapy practice across Australia has evolved towards a relatively low use of HDR brachytherapy (ratio of HDR to LDR brachytherapy < 0.5 for all jurisdictions except the Australian Capital Territory).

Conclusion

Rates of PLND and HDR brachytherapy for PCa have declined in Australia, providing evidence for the effect of stage migration due to widespread PSA screening. Currently, PSA screening rates remain high among older men, which may expose them to unnecessary investigations and treatment-related morbidity.